Market Cap 248.25B
Revenue (ttm) 51.72B
Net Income (ttm) 11.94B
EPS (ttm) N/A
PE Ratio 13.97
Forward PE 13.25
Profit Margin 23.09%
Debt to Equity Ratio 0.77
Volume 1,040,700
Avg Vol 1,675,624
Day's Range N/A - N/A
Shares Out 2.11B
Stochastic %K 62%
Beta 0.59
Analysts Sell
Price Target $116.38

Company Profile

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 324 11 11
Fax: 41 61 324 80 01
Address:
Lichtstrasse 35, Basel, Switzerland
tradingcalendar
tradingcalendar Jun. 24 at 6:41 PM
M&A Regulus Therapeutics $RGLS is being acquired by Novartis $NVS via tender offer - Shareholders to receive $7.00 cash per share + 1 CVR - CVR is equal to a future potential value of $7.00 per share - Shares of RGLS to be delisted after the close of extended hours trading tonight More Information : https://www.sec.gov/Archives/edgar/data/1505512/000110465925052756/tm2515290-1_sc14d9.htm
0 · Reply
ThomasLD
ThomasLD Jun. 24 at 6:27 PM
$GALT $GILD $NVS Impressive!!!
0 · Reply
Quantumup
Quantumup Jun. 24 at 5:09 PM
RBC Capital, on June 23,⬆️the PT on $ACAD to $38 from $26 and reiterated at an Outperform $AZN $NVS $AXSM PTCT RARE JAZZ $SLNO RYTM AARD RBC Capital said in its note, " $ACAD represents a solid commercial-stage story with an emerging pipeline, with a meaningful recent Nuplazid IP win providing a high likelihood of cash flow sustainability and commercial tailwinds of late suggesting some continued Nuplazid growth and Daybue stabilization prospects. Maturing commercial franchises, exposure to macro/policy issues (IRA, MFN), and higher risk to the next pipeline catalyst ('101 for PWS) add some complexity to the setup, but with the scarcity value of $1B + annual revenue from existing products now likely sustainable well into the next decade and at a <$4B cap, stock looks fundamentally undervalued and any pipeline contribution is likely all upside."
0 · Reply
SparkyReturns
SparkyReturns Jun. 24 at 3:26 PM
$JNJ Hey, Small cap investing idea: ICU recently beat down from a capital raise a few days ago, which was just reported will make them Nasdaq compliant. Waiting on confirmation. ICU has a unique SCD device which treats Acute Kidney Infection and has also been approved for compassionate and emergency use for Sepsis. FDA loves it so much has granted multiple breakthrough device designations, and has even awarded grants. Also Dept of Defense money to study use in burn or trauma cases. The device can calm the cytokine storm which can happen in a variety of conditions from AKI to sepsis to heart attacks to burn cases, Covid, etc. TAM in the tens of Billions. Current market cap approx. 8M. Read that again. Let that sink in. Reversal incoming. Cheers! $ABBV $NVO $NVS
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jun. 24 at 6:17 AM
$SLS $170M Mid Cap REGOR P1 CDKinase asset bought for $850M Cash + $4B more in milestones - here’s a few CdKinase inhibitors like SLS009. $PFE Pfizers' Ibrance - palbociclib CDKinase Inhibitor $NVS Novartis' Kisqali -ribociclib CDKinase Inhibitor $LLY Eli Lilly's Verzenio -abemaciclib CDKinase Inhibitor $SLS $170M SLS009 Tambiciclib CDKinase Inhibitor. the 'market' is about to appreciate this asset - FDA ACCELERATED NEWS INCOMING IN JUNE
2 · Reply
DonCorleone77
DonCorleone77 Jun. 23 at 10:33 AM
$NVS $RGLS Novartis announces expiration of HSR waiting period of Regulus offer Novartis (NVS) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Novartis' previously announced tender offer to acquire all of the outstanding shares of common stock of Regulus Therapeutics Inc. (RGLS), in exchange for $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus one contingent value right per share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone. The expiration of the HSR Act waiting period occurred at 11:59 p.m., New York City Time, on June 20. "Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 29, 2025, among Novartis, Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis, and Regulus, including the tender offer and the subsequent merger, which remain subject to the condition that there be validly tendered and not validly withdrawn, immediately prior to the Expiration Time a number of Shares that, together with any Shares then owned by Novartis, Purchaser or any of their direct or indirect wholly owned subsidiaries, represents at least one more Share than 50% of the total number of all the outstanding Shares immediately prior to the Expiration Time. The offer will expire one minute past 11:59 p.m., New York City Time, on June 24, 2025, unless the tender offer is otherwise extended or earlier terminated," the company stated.
2 · Reply
onestudy
onestudy Jun. 22 at 10:57 PM
$CPHI Featured Alongside Global Pharma Leaders: According to the official Jinan government website, CPHI’s bacterial infection treatment was listed under the city’s supervised drug pricing catalogue on June 3, 2025. This inclusion means the product is now available in Jinan’s regulated public healthcare system, a city with a population of over 9 million. In the same list, major global pharmaceutical companies are also featured: 1. $NVS (Novartis): Complex Substitution – likely a specialty cardiovascular or metabolic drug. 2. $BLCO (Bausch + Lomb): Runshu Eye Drops – used for eye dryness and irritation relief. 3. $BAYRY (Bayer): Glucobay (Acarbose) – an oral medication used to treat type 2 diabetes. 4. $SNY (Sanofi): Amlodipine (Amory) – a blood pressure and angina medication. ....and many more. All these drug companies are expanding presence within China’s public healthcare and pharmaceutical retail network.
2 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jun. 21 at 10:46 PM
$SLS Phase 3, FDA Registrational Trial Results - Worth Literally $10B + to Big Pharma Will BE Announced - ANY DAY NOW. GPs, an Immunotherapy for AML Remission Maintenance - 5 years in the Making and Imminent. - at the ASM CEO Disclosed patients on GPs are Living 3+ Years - vs Dr's who Treat Actual P3 Control Patients Stating OS is Only 6-8 months with Best Available Treatments. Cash Runway into Q3, 2026 and More Cash Coming. This Short Manipulated $154M equity offers the Investment Opportunity of a Lifetime. Now up to 59 Institutional Funds Invested, holding 34% of FLOAT, vs 38 funds w 8% - Q3 2024. - INSIDERS PURCHASING on the Open Market - 99.9 to .01 CALL to Put Ratio. $PFE $NVS $LLY
0 · Reply
Theflash88
Theflash88 Jun. 21 at 5:32 PM
0 · Reply
Quantumup
Quantumup Jun. 20 at 7:40 PM
Goldman Sachs, on 6/16,🏁 $ELVN Buy-$37. $TERN $AAPG $TAK INCY $NVS PFE BMY AZN #EHA2025 Goldman Sachs said in its initiation report: "Given continued positive Ph1 data and the announcement of a planned Ph3 initiation in 2026 for tyrosine kinase inhibitor (TKI) ELVN-001 in chronic myeloid leukemia (CML), we assign a Buy rating to $ELVN with a $37, 12-month price target, from the previous Early-Stage Biotech designation." Goldman Sachs went on to say:
0 · Reply
Latest News on NVS
BioNTech says Novartis executive Zapata-Gomez to become CFO

May 5, 2025, 6:34 AM EDT - 7 weeks ago

BioNTech says Novartis executive Zapata-Gomez to become CFO

BNTX


Final Trade: NVS, XLU and SMMT

May 1, 2025, 6:20 PM EDT - 7 weeks ago

Final Trade: NVS, XLU and SMMT

SMMT XLU


Novartis to Acquire Regulus in $1.7 Billion Deal

Apr 30, 2025, 7:50 AM EDT - 7 weeks ago

Novartis to Acquire Regulus in $1.7 Billion Deal

RGLS


Novartis to buy Regulus Therapeutics for up to $1.7 billion

Apr 30, 2025, 7:25 AM EDT - 7 weeks ago

Novartis to buy Regulus Therapeutics for up to $1.7 billion

RGLS


Novartis AG (NVS) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 2:09 PM EDT - 2 months ago

Novartis AG (NVS) Q1 2025 Earnings Call Transcript


Pharma firms maastraz

Apr 29, 2025, 12:06 PM EDT - 2 months ago

Pharma firms maastraz

AZN GSK NVO


Novartis Lifts Guidance After Profit, Sales Top Views

Apr 29, 2025, 1:27 AM EDT - 2 months ago

Novartis Lifts Guidance After Profit, Sales Top Views


Novartis more upbeat on 2025 guidance after strong Q1 momentum

Apr 29, 2025, 1:12 AM EDT - 2 months ago

Novartis more upbeat on 2025 guidance after strong Q1 momentum


tradingcalendar
tradingcalendar Jun. 24 at 6:41 PM
M&A Regulus Therapeutics $RGLS is being acquired by Novartis $NVS via tender offer - Shareholders to receive $7.00 cash per share + 1 CVR - CVR is equal to a future potential value of $7.00 per share - Shares of RGLS to be delisted after the close of extended hours trading tonight More Information : https://www.sec.gov/Archives/edgar/data/1505512/000110465925052756/tm2515290-1_sc14d9.htm
0 · Reply
ThomasLD
ThomasLD Jun. 24 at 6:27 PM
$GALT $GILD $NVS Impressive!!!
0 · Reply
Quantumup
Quantumup Jun. 24 at 5:09 PM
RBC Capital, on June 23,⬆️the PT on $ACAD to $38 from $26 and reiterated at an Outperform $AZN $NVS $AXSM PTCT RARE JAZZ $SLNO RYTM AARD RBC Capital said in its note, " $ACAD represents a solid commercial-stage story with an emerging pipeline, with a meaningful recent Nuplazid IP win providing a high likelihood of cash flow sustainability and commercial tailwinds of late suggesting some continued Nuplazid growth and Daybue stabilization prospects. Maturing commercial franchises, exposure to macro/policy issues (IRA, MFN), and higher risk to the next pipeline catalyst ('101 for PWS) add some complexity to the setup, but with the scarcity value of $1B + annual revenue from existing products now likely sustainable well into the next decade and at a <$4B cap, stock looks fundamentally undervalued and any pipeline contribution is likely all upside."
0 · Reply
SparkyReturns
SparkyReturns Jun. 24 at 3:26 PM
$JNJ Hey, Small cap investing idea: ICU recently beat down from a capital raise a few days ago, which was just reported will make them Nasdaq compliant. Waiting on confirmation. ICU has a unique SCD device which treats Acute Kidney Infection and has also been approved for compassionate and emergency use for Sepsis. FDA loves it so much has granted multiple breakthrough device designations, and has even awarded grants. Also Dept of Defense money to study use in burn or trauma cases. The device can calm the cytokine storm which can happen in a variety of conditions from AKI to sepsis to heart attacks to burn cases, Covid, etc. TAM in the tens of Billions. Current market cap approx. 8M. Read that again. Let that sink in. Reversal incoming. Cheers! $ABBV $NVO $NVS
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jun. 24 at 6:17 AM
$SLS $170M Mid Cap REGOR P1 CDKinase asset bought for $850M Cash + $4B more in milestones - here’s a few CdKinase inhibitors like SLS009. $PFE Pfizers' Ibrance - palbociclib CDKinase Inhibitor $NVS Novartis' Kisqali -ribociclib CDKinase Inhibitor $LLY Eli Lilly's Verzenio -abemaciclib CDKinase Inhibitor $SLS $170M SLS009 Tambiciclib CDKinase Inhibitor. the 'market' is about to appreciate this asset - FDA ACCELERATED NEWS INCOMING IN JUNE
2 · Reply
DonCorleone77
DonCorleone77 Jun. 23 at 10:33 AM
$NVS $RGLS Novartis announces expiration of HSR waiting period of Regulus offer Novartis (NVS) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Novartis' previously announced tender offer to acquire all of the outstanding shares of common stock of Regulus Therapeutics Inc. (RGLS), in exchange for $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus one contingent value right per share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone. The expiration of the HSR Act waiting period occurred at 11:59 p.m., New York City Time, on June 20. "Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 29, 2025, among Novartis, Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis, and Regulus, including the tender offer and the subsequent merger, which remain subject to the condition that there be validly tendered and not validly withdrawn, immediately prior to the Expiration Time a number of Shares that, together with any Shares then owned by Novartis, Purchaser or any of their direct or indirect wholly owned subsidiaries, represents at least one more Share than 50% of the total number of all the outstanding Shares immediately prior to the Expiration Time. The offer will expire one minute past 11:59 p.m., New York City Time, on June 24, 2025, unless the tender offer is otherwise extended or earlier terminated," the company stated.
2 · Reply
onestudy
onestudy Jun. 22 at 10:57 PM
$CPHI Featured Alongside Global Pharma Leaders: According to the official Jinan government website, CPHI’s bacterial infection treatment was listed under the city’s supervised drug pricing catalogue on June 3, 2025. This inclusion means the product is now available in Jinan’s regulated public healthcare system, a city with a population of over 9 million. In the same list, major global pharmaceutical companies are also featured: 1. $NVS (Novartis): Complex Substitution – likely a specialty cardiovascular or metabolic drug. 2. $BLCO (Bausch + Lomb): Runshu Eye Drops – used for eye dryness and irritation relief. 3. $BAYRY (Bayer): Glucobay (Acarbose) – an oral medication used to treat type 2 diabetes. 4. $SNY (Sanofi): Amlodipine (Amory) – a blood pressure and angina medication. ....and many more. All these drug companies are expanding presence within China’s public healthcare and pharmaceutical retail network.
2 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jun. 21 at 10:46 PM
$SLS Phase 3, FDA Registrational Trial Results - Worth Literally $10B + to Big Pharma Will BE Announced - ANY DAY NOW. GPs, an Immunotherapy for AML Remission Maintenance - 5 years in the Making and Imminent. - at the ASM CEO Disclosed patients on GPs are Living 3+ Years - vs Dr's who Treat Actual P3 Control Patients Stating OS is Only 6-8 months with Best Available Treatments. Cash Runway into Q3, 2026 and More Cash Coming. This Short Manipulated $154M equity offers the Investment Opportunity of a Lifetime. Now up to 59 Institutional Funds Invested, holding 34% of FLOAT, vs 38 funds w 8% - Q3 2024. - INSIDERS PURCHASING on the Open Market - 99.9 to .01 CALL to Put Ratio. $PFE $NVS $LLY
0 · Reply
Theflash88
Theflash88 Jun. 21 at 5:32 PM
0 · Reply
Quantumup
Quantumup Jun. 20 at 7:40 PM
Goldman Sachs, on 6/16,🏁 $ELVN Buy-$37. $TERN $AAPG $TAK INCY $NVS PFE BMY AZN #EHA2025 Goldman Sachs said in its initiation report: "Given continued positive Ph1 data and the announcement of a planned Ph3 initiation in 2026 for tyrosine kinase inhibitor (TKI) ELVN-001 in chronic myeloid leukemia (CML), we assign a Buy rating to $ELVN with a $37, 12-month price target, from the previous Early-Stage Biotech designation." Goldman Sachs went on to say:
0 · Reply
Quantumup
Quantumup Jun. 20 at 5:50 PM
TD Cowen Named Buy Rated $ELVN as a Best Smidcap Idea and said "Strong Data Position '001 To Advance Care In $B+ CML Market" $TERN $AAPG $TAK $NVS PFE AZN BMY #EHA2025 TD Cowen additionally said, "ELVN-001 is designed to improve upon prior TKIs for CML. At EHA ELVN-001 produced strong proof-of-concept data with a high MMR rate and benign safety profile, positioning it to become a standard therapy in this multi-$B market. ELVN-001 will enter pivotal development in 2026 and we project peak sales of $3B. We think $ELVN is undervalued for '001's potential. It is a top smidcap biotech pick."
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jun. 19 at 6:04 PM
$SLS While We Wait for FDA Registrational Phase 3 Results - worth Literal Billions - Gps Immunotherapy will be getting the FDA GREEN LIGHT to a $6B TAM - Any Day Now $PFE Ibrance - Palbo-Ciclib CDKinase Inhibitor $NVS Kisqali - Ribo-Ciclib CDKinase Inhibitor $LLY Verzenio - Abema-Ciclib CDKinase Inhibitor $SLS $155M - Tambi-Ciclib CDKinase Inhibitor SLS009 FDA Pathway / STIFEL CoDEV News Expected in H1 Phase 2A ASH Publication OS of 8.8 months, already More than 350% + longer than Historical Norms of 2.5 months - and SAFE. Confirms 009 Leads to DURABLE OS - the Holy Grail for AML, everyone Hopes for ORR, CR and MRD-, status in order to Get to OS advantages, TambiCiclib / SLS009 Does it. 67% ORR in all Comer ASXL1+ AML-MRC Subtypes - Dr Z and K, were clear 009 only needed 25% Response Rates or better for FDA Approval .. its in at 67% Bottom LINE: TAMBICICLIB Will Be FDA Approved - the Market Has yet to appreciates its value.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 18 at 9:01 PM
$NVS stands out as a top-tier income play with a compelling 3.38% dividend yield backed by 12.4% YoY revenue growth and improving ROE (now 9.4%). Our AI analysis of 5700 stocks ranks Novartis in the top 30 dividend stocks due to its sustainable 65% payout ratio, below-sector P/E (18.5x), and pharmaceutical sector resilience. The 28% QoQ net income jump shows capacity to maintain payouts through market cycles. See full analysis and our other top dividend picks at aipha.io - no signup required.
0 · Reply
Fingerlickengood
Fingerlickengood Jun. 17 at 6:05 PM
$CDXS $NVS https://www.medscape.com/viewarticle/this-drug-statin-alternative-2025a1000g4k
2 · Reply
Dumb_money_big_gains
Dumb_money_big_gains Jun. 17 at 5:21 PM
$ARTV lots of biotech acquisitions happening lately… $AZN $LLY $NVS
0 · Reply
Estimize
Estimize Jun. 17 at 2:01 PM
Wall St is expecting 2.31 EPS for $NVS Q2 [Reporting 07/17 BMO] http://www.estimize.com/intro/nvs?chart=historical&metric_name=eps&utm_cont
0 · Reply
clan
clan Jun. 16 at 8:58 PM
MNKD-101 nears. If just 25% of the total market is captured, with a 70% Profit Margin and conservatively a 20 PE, this adds $24/sh to $MNKD . CLOFAZIMINE (CIS) by Mannkind ----------------------------------------------------- Designations: - Phase 3 ICoN-1 trial - Fast Tracked by FDA - Orpan Drug - Qualified Infectious Disease Product - Well tolerated - No significant Adverse Events - Localized treatment (lungs) - Improved patient adherence - Indications for arthritis & CANCERs - Current global mkt $2.1B [2023] ...and coming soon..... - - - Clofazimine DPI No red skin (or green). Partner with $GSK ? $NVS ? $RHHBY ?
3 · Reply
clan
clan Jun. 16 at 5:12 PM
$MNKD MNKD-901 Coming to a press release near you soon! Existing drug; inhalable version. 🚫💉 $MRK $JNJ $NVS
0 · Reply
DonCorleone77
DonCorleone77 Jun. 12 at 10:38 AM
$NVS Novartis announces results from APPULSE-PNH study of Fabhalta Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta in adult patients with paroxysmal nocturnal hemoglobinuria with Hb levels greater than or equal to10g/dL who switched from anti-C5 therapies. After 24 weeks of treatment with Fabhalta, the Hb level improved on average by 2.01 g/dL with most patients achieving normal or near-normal levels. Data will be presented at the European Hematology Association, EHA, Congress 2025. In the Phase IIIB APPULSE-PNH study, adult patients with paroxysmal nocturnal hemoglobinuria who switched to Fabhalta experienced clinically meaningful improvements in hemoglobin levels of 2.01 g/dL on average. APPULSE-PNH evaluated Fabhalta in a population with higher baseline hemoglobin levels than those enrolled in the pivotal Phase III program, expanding the clinical evidence base. No patients treated with Fabhalta required transfusions, experienced breakthrough hemolysis or had any major adverse vascular events during the treatment period. Patients treated with Fabhalta reported an average improvement in fatigue from baseline of 4.88 points at Day 84 and 4.29 points at Day 168 of the study.
0 · Reply
fred898w
fred898w Jun. 12 at 3:31 AM
$NVS back to 115 Friday
0 · Reply
DonCorleone77
DonCorleone77 Jun. 11 at 10:02 PM
$AZN $GSK $NVS $RHHBY $BMY RFK Jr. names new CDC vaccine advisory panel picks, STAT reports HHS Secretary Robert F. Kennedy Jr. announced eight new members that will sit on the expert panel that advises the Centers for Disease Control and Prevention, or CDC, on vaccine policy, and "said they would review the current vaccine schedule, as well as evaluate new shots." These appointments follow Kennedy dismissing every member of the committee just days ago. Publicly traded companies in the space include the following: AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
0 · Reply
SilverEagle
SilverEagle Jun. 11 at 3:03 PM
$NVS new ATHs soon
0 · Reply